GLP-1 Weight-Loss Plateau: What to Track When the Scale Stops Moving

For months, the pattern may have felt reassuring.

Your weight was gradually moving down.

Then something changes.

The scale stays almost exactly the same for a week.

Then another week.

Maybe another.

You are still taking your medication, but the numbers no longer look the way they did at the beginning.

That can lead to a familiar question:

“Has my GLP-1 stopped working?”

Not necessarily.

Weight loss does not usually continue at the same rate indefinitely, even when treatment remains effective.

Clinical trials of both semaglutide and tirzepatide show that weight reduction tends to slow over time and eventually approaches a plateau. The important clinical question is therefore not simply whether today's scale reading changed.

It is:

What does the longer treatment trajectory show, and what else changed around the same time?

What Does a GLP-1 Weight-Loss Plateau Actually Mean?

There is no single universally accepted number of days or weeks that defines a weight-loss plateau for every patient.

A few days without weight loss is not a plateau.

One higher weigh-in is not a plateau.

Even several weeks of relatively stable weight may need to be interpreted in the context of normal fluctuations, treatment stage, starting weight, dose, eating patterns, and other clinical factors.

Researchers often need much stricter definitions.

For example, a 2025 analysis of the SURMOUNT-1 and SURMOUNT-4 tirzepatide trials defined weight plateau as less than 5% weight change over a 12-week interval and all subsequent 12-week intervals.

That is very different from deciding that treatment has failed because the scale has not changed since last Monday.

What Semaglutide Research Shows about Plateaus

The STEP 5 trial followed adults receiving semaglutide 2.4 mg for 104 weeks.

Participants receiving semaglutide lost an average of 15.2% of their baseline body weight by week 104, compared with 2.6% with placebo.

But the shape of the weight-loss curve is particularly important.

Weight fell substantially during the earlier phase of treatment and then plateaued at approximately week 60. That lower weight was largely maintained through the remainder of the two-year trial.

In other words:

The plateau was not evidence that semaglutide had suddenly stopped working.

Continued treatment was associated with maintenance of the substantial weight reduction that participants had already achieved.

This distinction matters.

During the early phase of treatment, success may look like:

Weight moving downward.

Later, successful treatment may increasingly look like:

Previously lost weight remaining off.

What Tirzepatide Research Shows about Plateaus

A dedicated 2025 analysis examined time to weight plateau among tirzepatide-treated participants in the SURMOUNT-1 and SURMOUNT-4 trials.

In SURMOUNT-1, the median time to plateau varied according to baseline BMI category.

It was approximately:

24.3 weeks for participants with overweight

26.0 weeks for participants with class I obesity

36.1 weeks for participants with class II obesity

36.1 weeks for participants with class III obesity

By week 72, approximately 88% to 90% of participants across BMI categories had reached a weight plateau according to the study's predefined criteria.

Higher tirzepatide doses, younger age, and female sex were associated with reaching the plateau later in that analysis.

The key point is not that everyone will plateau at one specific week.

It is that plateauing was common even among people successfully treated with tirzepatide.

Why Does Weight Loss Slow Down?

A plateau is not necessarily evidence of medication failure.

Body weight is regulated by a complex interaction between energy intake, energy expenditure, appetite, body composition, hormones, and other physiological processes.

As body weight falls, the body does not remain metabolically identical to where it started.

Energy Requirements Change

A smaller body generally requires less energy to maintain than a larger one.

This means the energy deficit that produced faster weight loss earlier in treatment may become smaller as weight decreases.

Appetite Regulation Adapts

Weight loss itself can activate biological mechanisms that push appetite upward.

A 2024 mathematical-modeling study compared weight-loss trajectories produced by calorie restriction, semaglutide, tirzepatide, and bariatric surgery.

The analysis suggested that GLP-1-based therapies substantially weaken the appetite feedback response that normally opposes weight loss, allowing weight loss to continue for longer than diet restriction alone.

However, that feedback is not eliminated completely, which helps explain why weight eventually approaches a new equilibrium.

This was a modeling study rather than a direct clinical trial, so it should be interpreted as a physiological framework rather than proof of exactly what happens in every individual.

The Same Treatment Can Produce a Different Rate of Change over Time

The first months of treatment and the second year of treatment should not necessarily be expected to produce identical rates of weight loss.

This is why comparing:

“How much did I lose this month?”

with:

“How much did I lose during my first month?”

may create unrealistic expectations.

Before Calling It a Plateau, Look at the Weight Trend

The first thing worth examining is not today's weight.

It is the trajectory.

Imagine these measurements:

84.1 → 83.8 → 84.0 → 83.6 → 83.9 kg

That may feel frustrating.

But whether it represents a meaningful plateau depends on what came before and what happens next.

Now compare:

Four months ago: 91.2 kg

Three months ago: 88.7 kg

Two months ago: 86.1 kg

One month ago: 84.3 kg

Current: 83.9 kg

The recent rate of loss has slowed considerably, but the larger treatment trajectory still shows substantial progress.

Use Peptimize to See the Trend

With Peptimize, keep your weight measurements connected over time instead of judging treatment from isolated weigh-ins.

The useful question becomes:

“What has my trend done over the last 4, 8, or 12 weeks?”

rather than:

“Why did I not lose weight today?”

For more context on interpreting progress beyond the scale, internally link here to Beyond the Scale: 8 Ways to Track GLP-1 Progress.

1. Track Your Medication and Treatment Stage

A weight plateau means very different things depending on where you are in treatment.

Record:

• Medication
• Current prescribed dose
• Date treatment started
• How long you have been on the current dose
• Previous dose changes
• Missed or delayed doses

Someone still moving through titration is not in the same treatment phase as someone who has remained on a stable maintenance dose for many months.

Current prescribing information for both Wegovy and Zepbound uses structured dose escalation and directs clinicians to consider treatment response and tolerability when selecting ongoing dosing.

Do not increase your dose independently because weight loss has slowed.

A plateau is information for a clinical review, not an instruction to self-escalate.

2. Track Appetite and Fullness

Weight trend is only one part of the picture.

Ask whether anything has changed in your appetite.

For example:

• Are portions becoming larger?
• Do you become hungry sooner?
• Does fullness last for less time?
• Are you snacking more frequently?
• Are meals less satisfying?
• Has nothing changed at all?

These patterns matter because a plateau with stable appetite and eating behavior provides different information from a plateau accompanied by a marked increase in hunger.

If appetite suppression has become noticeably weaker, internally link here to When Appetite Suppression Fades on GLP-1: What Should You Track before Your Next Appointment?

3. Track Food Noise Separately from Hunger

Physical hunger and food-related thoughts are related, but they are not exactly the same thing.

Some people describe persistent thoughts about meals, cravings, or eating as food noise.

During a plateau, ask:

• Is food occupying more mental space?
• Are cravings becoming more frequent?
• Are you thinking about snacks more often?
• Has physical hunger changed too?
• Did food noise return before or after the weight trend flattened?

This helps separate:

Weight plateau + stable food noise

from:

Weight plateau + increasing hunger + increasing food noise

Those are different patterns and may lead to different clinical conversations.

4. Review Your Dose-Change Timeline

Dose changes are useful landmarks.

Instead of remembering:

“My weight stopped moving recently.”

you may discover:

Dose changed → appetite changed → side effects changed → weight continued falling → weight later stabilized

or:

Dose unchanged for several months → appetite gradually increased → weight trend flattened

These timelines are much more informative.

Use Peptimize as your GLP-1 dose tracker so medication changes remain connected with your weight and symptom history.

For more detail, internally link this section to GLP-1 Dose Increase: What Can Change after Titration?

5. Check Injection Adherence and Treatment Interruptions

Before interpreting a plateau, make sure the medication timeline itself is accurate.

Review:

• Missed injections
• Delayed injections
• Treatment interruptions
• Restarting after missed doses
• Changes in your usual treatment schedule

A few missed weeks can make a treatment period difficult to interpret accurately.

Do not compensate for missed medication by changing your dose or schedule unless instructed to do so according to your product's prescribing information or by your healthcare professional.

Keeping an accurate GLP-1 injection log makes this easier.

Internally link here to Your GLP-1 Injection-Day Log: What Is Worth Recording?

6. Review Side Effects and Tolerability

Weight loss is not the only variable relevant to treatment decisions.

Your clinician also needs to understand how well you are tolerating therapy.

Track meaningful symptoms such as:

• Nausea
• Vomiting
• Constipation
• Diarrhea
• Bloating
• Abdominal discomfort
• Reflux
• Injection-site reactions

This matters because a dose decision should not be made from the scale alone.

For example, a person experiencing a plateau with minimal adverse effects presents a different treatment picture from someone with a plateau plus significant persistent gastrointestinal symptoms.

For a structured symptom approach, internally link to How to Track GLP-1 Side Effects and Spot Patterns over Time.

7. Look at Body Measurements and Non-Scale Changes

Body weight is useful, but it is not the only measure of physical change.

Depending on your treatment goals, you may also notice:

• Waist measurement changing
• Clothing continuing to fit differently
• Improved physical function
• Increased strength
• Better exercise tolerance
• Changes in body composition

A stable scale does not automatically mean that nothing is changing.

At the same time, non-scale victories should not be used to dismiss a sustained plateau that requires clinical review.

Think of them as additional context.

8. Review What Changed in Your Routine

Before attributing every plateau to the medication, look at what else changed.

Useful areas to review include:

• Meal patterns
• Portion sizes
• Snacking
• Protein intake
• Alcohol intake
• Hydration
• Physical activity
• Strength training
• Sleep
• Stress
• Travel or changes in routine

The goal is not to blame yourself for a plateau.

It is to identify variables that may help explain the overall pattern.

A medication can remain pharmacologically active while eating behavior, activity, or energy requirements change over time.

A Plateau with Good Appetite Control Is Different from a Plateau with Returning Hunger

This distinction is especially useful.

Consider two people.

Pattern A

Weight: stable for six weeks

Appetite: well controlled

Food noise: minimal

Medication: unchanged

Adherence: consistent

Pattern B

Weight: stable for six weeks

Appetite: gradually increasing

Food noise: returning

Portions: becoming larger

Medication: unchanged

Both people may describe themselves as being “stuck.”

But they are not presenting the same treatment pattern.

This is why tracking several variables together is more useful than tracking body weight alone.

Does a Plateau Mean Semaglutide Has Stopped Working?

Not necessarily.

STEP 5 provides a clear example.

Weight reduction with semaglutide 2.4 mg plateaued around week 60, but that substantial weight reduction was maintained through week 104 with continued treatment.

Mean weight reduction at week 104 remained approximately 15.2% from baseline.

The plateau therefore represented a change in the rate of weight loss, not necessarily disappearance of treatment benefit.

This also helps explain why maintenance of lost weight can itself be an important treatment outcome.

Does a Tirzepatide Plateau Mean Zepbound or Mounjaro Has Stopped Working?

Again, not necessarily.

The dedicated SURMOUNT plateau analysis showed that most participants eventually reached a predefined plateau while continuing tirzepatide treatment.

Plateau timing varied considerably between participants and BMI categories.

This makes it inappropriate to use a universal rule such as:

“If you have not lost anything for four weeks, tirzepatide has stopped working.”

The treatment trajectory needs to be interpreted in context.

Do Not Change Injection Site to Try to Break a Plateau

Another common idea in online GLP-1 communities is:

“Switch from your thigh to your stomach and the weight loss will start again.”

Current evidence does not establish changing between approved injection regions as a treatment for a weight plateau.

Research on semaglutide and tirzepatide suggests comparable overall drug exposure across approved abdominal, thigh, and upper-arm administration regions.

For a detailed evidence review, internally link here to GLP-1 Injection Sites: Abdomen vs Thigh vs Arm, Does the Site Actually Matter?

Changing an injection site may be appropriate for normal site rotation, but it should not be presented as an evidence-based method for restarting weight loss.

Do Not Chase Side Effects Either

Another misconception is that treatment should feel stronger when it is working.

For example:

“I used to get nausea and now I do not, so maybe the medication stopped working.”

Clinical evidence does not support using gastrointestinal adverse effects as a marker of efficacy.

Studies of both semaglutide and tirzepatide found meaningful weight reduction among participants who did not experience common gastrointestinal adverse events.

Internally link here to No Side Effects on GLP-1: Does That Mean It Isn't Working?

The absence of nausea does not explain a plateau by itself.

What Should You Bring to Your Next Appointment?

Instead of arriving with:

“My GLP-1 stopped working.”

a more clinically useful summary might be:

Medication: Zepbound

Current dose: prescribed maintenance dose

Time on current dose: 12 weeks

Weight trend: approximately stable for 7 weeks

Previous 6-month change: substantial downward trend

Appetite: slightly increased over last month

Food noise: more noticeable

Injection adherence: no missed doses

Side effects: minimal

Activity: stable

Other changes: none obvious

That gives your clinician much more information than a single scale reading.

Peptimize can help preserve these variables in one treatment history so you do not have to reconstruct months of information before an appointment.

When Should a Plateau Be Reviewed Clinically?

You do not need to panic when weight remains unchanged for several days.

However, a sustained change in your trajectory is worth discussing with your healthcare provider, particularly when accompanied by:

• Meaningful weight regain
• Substantial appetite changes
• Increased food noise
• New or persistent side effects
• Treatment interruptions
• Concerns about medication adherence
• Changes in glucose control if you have diabetes
• Questions about whether your current dose remains appropriate

Treatment decisions should consider your entire clinical response, not only the number on the scale.

Where Peptimize Fits

The value of Peptimize during a plateau is not that it can tell you why your weight stopped moving.

It cannot diagnose the cause of a plateau or tell you to increase your medication.

Its role is to help you organize the evidence surrounding the plateau.

Keep your:

• Medication
• Dose history
• Injection history
• Weight trend
• BMI
• Side effects
• Progress

together.

Instead of:

“I think I have been stuck for a while.”

you can see:

“My weight trend flattened six weeks ago, my dose has been unchanged for 14 weeks, my injections have been consistent, and my appetite started increasing three weeks ago.”

That is the kind of pattern that becomes useful.

The Clinical Bottom Line

A GLP-1 weight-loss plateau is not automatically evidence of treatment failure.

Long-term clinical trials demonstrate that weight reduction naturally slows and plateaus during successful pharmacological treatment.

In STEP 5, semaglutide-associated weight reduction plateaued around week 60 and remained largely maintained through two years.

In a SURMOUNT analysis, most tirzepatide-treated participants eventually reached a predefined weight plateau, with the timing varying between individuals.

Physiological modeling also suggests that plateaus reflect the interaction between continued treatment effects and biological mechanisms that increasingly oppose further weight loss as body weight declines.

So when the scale stops moving, do not immediately conclude:

“My GLP-1 has stopped working.”

Instead, look at:

Weight trend.

Treatment stage.

Dose history.

Injection adherence.

Appetite.

Food noise.

Side effects.

Body measurements.

Changes in routine.

Then review the full pattern with the healthcare professional managing your treatment.

Track the Plateau, Not Just the Number

A plateau is a period in your treatment history.

It should not be reduced to one frustrating weigh-in.

With Peptimize, you can keep your medication, doses, injections, weight, BMI, side effects, and progress connected so that when your weight trajectory changes, you have the context to understand what changed around it.

When the scale stops moving, zoom out before you draw a conclusion.

Frequently Asked Questions

Is It Normal to Hit a Plateau on GLP-1 Medication?

Yes. Long-term clinical trials with semaglutide and tirzepatide show that weight reduction generally slows and eventually approaches a plateau during continued treatment.

How Long Does a GLP-1 Weight-Loss Plateau Last?

There is no single duration that applies to everyone. Plateau timing varies according to treatment, individual response, starting weight, dose, and other factors. A few days or one week without weight loss should not automatically be considered a plateau.

When Does Semaglutide Weight Loss Plateau?

In the STEP 5 trial, average weight reduction with semaglutide 2.4 mg plateaued at approximately week 60 and was largely maintained through week 104.

When Does Tirzepatide Weight Loss Plateau?

In a post-hoc analysis of SURMOUNT-1, median time to plateau ranged from approximately 24 to 36 weeks across baseline BMI categories using the study's predefined plateau criteria. Individual experiences vary substantially.

Does a Wegovy Plateau Mean It Has Stopped Working?

Not necessarily. Semaglutide clinical-trial data show that weight can stabilize while substantial previous weight reduction remains maintained.

Does a Zepbound Plateau Mean I Need a Higher Dose?

Not automatically. Dose selection should consider treatment response, tolerability, prescribing information, and your healthcare provider's assessment. Do not independently increase your dose.

Can Changing My GLP-1 Injection Site Break a Plateau?

There is no established clinical evidence that changing between approved injection regions reliably restarts weight loss.

What Should I Track during a GLP-1 Plateau?

Useful information includes your longer-term weight trend, medication, dose history, injection adherence, appetite, food noise, side effects, body measurements, and meaningful changes in eating, activity, sleep, or routine.

Can Peptimize Tell Me Why My Weight Has Plateaued?

No. Peptimize is a tracking and organizational tool. It cannot diagnose the cause of a plateau or recommend medication changes. It can help you maintain a structured treatment history to review with your healthcare provider.

Selected Evidence

Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022. Semaglutide 2.4 mg produced a mean 15.2% body-weight reduction at week 104. Weight reduction plateaued at approximately week 60 and was maintained through the remainder of the trial.

Horn DB, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clinical Obesity. 2025. Most tirzepatide-treated participants eventually reached a predefined plateau, with median time to plateau varying according to baseline BMI and other characteristics.

Hall KD. Physiology of the weight-loss plateau in response to diet restriction, GLP-1 receptor agonism, and bariatric surgery. Obesity. 2024. Mathematical modeling suggests that weight plateaus reflect interactions between intervention effects, energy expenditure, and biological appetite feedback that strengthens as weight is lost.

Wharton S, et al. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity. 2023. Semaglutide was associated with sustained improvements in several measures of craving control during long-term treatment.

Medical Disclaimer: This article is intended for general educational purposes and does not provide medical advice, diagnosis, weight-loss targets, or medication recommendations. Peptimize is a tracking and organizational tool and does not determine why weight loss has plateaued or recommend dose changes. Do not increase, decrease, stop, or alter the schedule of semaglutide, tirzepatide, or another prescription medication without guidance from a qualified healthcare professional.